BRAIN and NERVE Shinkei Kenkyu no Shinpo Volume 71, Issue 6 (June 2019)

Complement-Mediated Mechanism and Complement Inhibitors in Guillain-Barré Syndrome Motoi Kuwahara 1 , Susumu Kusunoki 1 1Department of Neurology, Kindai University, Faculty of Medicine Keyword: ギラン・バレー症候群 , 補体阻害薬 , エクリズマブ , JET-GBS , 予後 , Guillain-Barré syndrome , complement inhibitors , eculizumab , Japanese Eculizumab Trial for GBS , prognosis pp.581-587
Published Date 2019/6/1
  • Abstract
  • Look Inside
  • Reference


Complement activation is involved in the pathogenetic mechanism of Guillain-Barré syndrome (GBS). To date, the effectiveness of complement inhibitors for GBS has been shown by in vitro and in vivo studies. A recent Japanese randomized controlled trial with eculizumab, a monoclonal antibody against the complement C5, indicated that eculizumab might improve the outcomes of GBS patients at six months from onset. In future, the prognosis of severe GBS cases may possibly be improved by a novel therapy targeting the complement.

Copyright © 2019, Igaku-Shoin Ltd. All rights reserved.


BRAIN and NERVE-神経研究の進歩
71巻6号 (2019年6月)
電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院